194423-15-9

Basic information

• Product Name: 4-[(3-BROMOPHENYL)AMINO]-6-ACRYLAMIDOQUINAZOLINE
• Synonyms: 4-[(3-BROMOPHENYL)AMINO]-6-ACRYLAMIDOQUINAZOLINE;PD 168393;N-[4-[(3-Bromophenyl)amino]-6-quinazolinyl]-2-propenamide;2-Propenamide, N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-;N-(4-((3-Bromophenyl)amino)quinazolin-6-yl)acrylamide
• CAS NO: 194423-15-9
• Molecular Formula: C₁₇H₁₃BrN₄O
• Molecular Weight: 369.22
• Product Categories: Inhibitors
• Mol File: 194423-15-9.mol
• Article Data: 13

Chemical Properties

• Melting Point: 279℃
• Appearance: /
• Storage Temp.: -20°C
• Solubility: insoluble in H2O; ≥1 mg/mL in EtOH with gentle warming and ultrasonic; ≥18.45 mg/mL in DMSO
• CAS DataBase Reference: 4-[(3-BROMOPHENYL)AMINO]-6-ACRYLAMIDOQUINAZOLINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-[(3-BROMOPHENYL)AMINO]-6-ACRYLAMIDOQUINAZOLINE(194423-15-9)
• EPA Substance Registry System: 4-[(3-BROMOPHENYL)AMINO]-6-ACRYLAMIDOQUINAZOLINE(194423-15-9)

Safety Data

• Hazardous Substances Data: 194423-15-9(Hazardous Substances Data)

Usage

Uses

Different sources of media describe the Uses of 194423-15-9 differently. You can refer to the following data:
1. PD 168393, is an irreversible epidermal growth factor receptor (EGFR) inhibitor.
2. PD168393 has been used in the acute inhibition of ErbB4.

Definition

ChEBI: A member of the class of quinazolines carrying bromoanilino and acrylamido substituents at positions 4 and 6 respectively.

Biochem/physiol Actions

PD168393 is a 6-acrylamido-4-anilinoquinazoline compound. It increases apoptosis in malignant peripheral nerve sheath tumor cells, stimulated by lysosomal dysfunction.

Upstream product

• 79-10-7 acrylic acid 
• 169205-78-1 6-amino-4-[(3-bromophenyl)amino]quinazoline 
• 814-68-6 acryloyl chloride 
• 17420-30-3 5-nitroanthranilonitrile 
• 169205-77-0 6-nitro-4-(3-bromophenylaniline)quinazoline 
• 256409-22-0 4-(3-bromo phenyl amine)-6-(3-methylthio propionyl amine)-quinazoline 
• 256409-20-8 4-(3-bromophenylamino)-6-(3-methoxypropionylamide)-quinazoline 
• 256409-24-2 4-(3-bromophenylamine)-6-(3-methylsulfoxidopropionylamide)-quinazoline 

Downstream Products

• 198961-89-6 N⁴-(3-bromophenyl)-N⁶-[3-(4-morpholinyl)propyl]-4,6-quinazolinediamine 
• 198961-88-5 N-[4-[(3-bromophenyl)-amino]-quinazolin-6-yl]-3-morpholino-propylamide 

Relevant articles and documents

Synthesis and biological evaluation of 4-anilinoquinolines as potent inhibitors of epidermal growth factor receptor

The mutant receptor tyrosine kinase EGFR is a validated and therapeutically amenable target for genotypically selected lung cancer patients. Here we present the synthesis and biological evaluation of a series of 6- and 7-substituted 4-anilinoquinolines as potent type I inhibitors of clinically relevant mutant variants of EGFR. Quinolines 3a and 3e were found to be highly active kinase inhibitors in biochemical assays and were further investigated for their biological effect on EGFR-dependent Ba/F3 cells and non-small cell lung cancer (NSCLC) cell lines.

INREVERSIBLE PROTEIN TYROSINE KINASES INHIBITORS AND THE PREPARATION METHODS AND USES THEREOF

The compounds which could inhibit protein tyrosine kinases activity or the pharmaceutical acceptable salts or hydrates thereof. The uses of the compounds in treating or preventing physiological abnormal induced by protein tyrosine kinases overexpression in mammal. The preparation methods of the compounds.

SUBSTITUTED QUINAZOLINE DERIVATIVES

This invention provides a process for preparing compounds of formula (1) wherein: X is phenyl optionally substituted with one or more substituents selected from the group consisting of halogen, alkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, hydrox